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AbstrACt
Objectives Moderation of alcohol consumption is included 
as a class I, level of evidence A recommendation in the 
current European guidelines for the management of 
hypertension. We investigated its awareness and self-
reported implementation among European physicians 
across different specialties and workplaces.
Design and setting A cross-sectional survey study 
conducted in two annual German meetings (German 
Society of Cardiology and the German Society of Internal 
Medicine) and two annual European meetings (European 
Society of Hypertension and European Society Cardiology) 
in 2015.
Participants 1064 physicians attending the European 
meetings were interviewed including 52.1% cardiologists, 
29.2% internists and 8.8% general practitioners.
Main outcome measures Physician screening of alcohol 
consumption, awareness and self-implementation of the 
recommendation of the current European guidelines about 
moderation of alcohol consumption for the management of 
hypertension.
results Overall, 81.9% of physicians reported to 
generally quantify alcohol consumption in patients 
with hypertension. However, only 28.6% and 14.5% of 
participants reported screening alcohol consumption in 
their patients with newly detected or treatment-resistant 
hypertension. Physicians recommended a maximum 
alcohol intake of 13.1±11.7 g/day for women (95% CI 
12.3 to 13.8) and 19.9±15.6 g/day for men (95% CI 
18.8 to 20.9). In case of moderate to high alcohol 
consumption, 10.3% would manage only hypertension 
without addressing alcohol consumption, while 3.7% of 
the physicians would do so in case of alcohol dependence 
(p<0.001).
Conclusions The average amount of alcohol intake 
per day recommended by European physicians in this 
survey was in agreement with the guidelines. The low 
number of physicians that screen for alcohol consumption 
in patients with newly detected and with treatment-
resistant hypertension indicates an important deficit in the 
management of hypertension.
IntrODuCtIOn 
High blood pressure (BP) or hypertension 
represents a main non-communicable risk 
factor for global burden of disease.1 In 2015, 
the global age-standardised prevalence of 
raised BP was 24.1% in men and 20.1% in 
women,2 affecting more than one billion 
subjects worldwide3 and thus constituting a 
primary health concern.3 The harmful use 
of alcohol accounts for 5.1% of the global 
burden of disease and injury, measured 
in disability-adjusted life years,4 5 and for 
3.3 million deaths every year, representing 
5.9% of all deaths worldwide.5 Among the 
more than 200 diseases and injuries for 
which alcohol causality is well established,6 
we also find a linear relationship between 
elevated BP and alcohol consumption.7 8 The 
exact mechanism of alcohol-induced hyper-
tension is complex9 and on a molecular 
level still largely unknown.9 On one hand, 
alcohol seems to increases the tendency to 
vasoconstriction due to an impairment of 
the baroreceptors10 11 and imbalance of the 
strengths and limitations of this study
 ► Identifying deficits in the management of alcohol 
consumption among European physicians attending 
annual scientific meetings in the field of cardiovas-
cular or internal medicine indicates a need to devel-
op better future alcohol interventions.
 ► The majority of physicians participating in this survey 
were hospital  based (78.5%), although outpatient 
care in the ambulatory setting plays a predominate 
role in the long-term management of hypertension.
 ► Answers were self-reported in a face-to-face in-
terview, which might have shifted some results up-
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central nervous system regulation, resulting in enhanced 
sympathetic activity.12 In addition, alcohol consumption 
increases also cortisol levels and stimulates the renin–
angiotensin–aldosterone system.13 The chronic alco-
hol-induced elevation of angiotensin II has been shown 
in rodents to directly cause inflammation and endothelial 
injury through increase of oxidative stress.14 15 This, on 
the other hand, leads to inhibition of endothelium-de-
pendent nitric oxide production and thus to endothelial 
dysfunction with impaired vasodilation.16 17 
Accordingly, moderation of alcohol consumption to 
no more than 20–30 g of alcohol per day in men and 
10–20 g of alcohol per day in women was one of the six 
recommended lifestyle changes in the current European 
Society of Hypertension (ESH) and European Society 
of Cardiology (ESC) guidelines for the management of 
arterial hypertension18 (online supplementary table 1). 
While not done in the previous edition in 2007 and its 
reappraisal in 2009, the last available guidelines (2013) 
graded the strength of this six recommended lifestyle 
changes for the first time with a class I evidence level A.
Currently, BP control rates in patients treated with 
hypertension across Europe are insufficient, with less 
than 50% of the patients achieving BP goals,19–21 and 
alcohol seems to be the least intervened factor in the 
management of hypertension.22–24 According to the 
latest WHO status report on alcohol and health,6 the 
amount of alcohol consumed in the European Region is 
almost twice the worlds average.6 Thus, efforts aiming to 
improve BP control, specifically through interventions in 
the management of alcohol consumption, are justified. 
Furthermore, the impact of screening and brief interven-
tions for alcohol use in primary care have been proven 
positive in many European projects,25 26 such as the 
Primary Health care European Project on Alcohol27 and 
the Optimizing Delivery of Health care Interventions.28 29
Against this background, we conducted a survey to inves-
tigate, by European physicians across different special-
ties and workplaces, screening of alcohol consumption, 
awareness and self-implementation of the recommenda-
tion to moderate alcohol consumption in their patients 
with hypertension.
MethODs
The survey collected data during four annual congresses 
between April and October 2015. Two of the meetings 
were German (meeting of the German Society of Cardi-
ology (DGK)30 and the German Society of Internal Medi-
cine (DGIM)31), and two were European (ESH32 and 
ESC).33 Attending physicians willing to participate were 
interviewed in German in the two German meetings and 
in English at the two European meetings. The complete 
questionnaire consisted of two parts: the first containing 
10 (online supplementary table 2) and the second 6 ques-
tions (table 1), respectively. Basic demographic data of 
Table 1 Questionnaire items included in this study (corresponding to part 2 of the original survey)
Items Topic Answers
Q11 Do you quantify alcohol consumption in your 
patients with hypertension?
Yes/no
Q12 When do you ask for alcohol consumption in 
patients with hypertension? (multiple answers 
possible)
In patients with newly detected hypertension.
In patients with hypertension and very high pressure.
In patients with treatment-resistant hypertension.
Other: Please specify (free-text answers were sorted among 
others in categories like ‘Rarely-never’/ ‘Always-regularly’ for 
further analysis).
Q13 What actions will you take when you diagnose 
someone with hypertension and moderate or high 
alcohol consumption? (no alcohol dependence: 
asked in the next question)
Manage and treat both problems yourself.
Manage only hypertension.
Manage only hypertension and refer to a general practitioner for 
the management of alcohol problems.
Manage only hypertension and refer to specialist care for alcohol 
problems.
Other (specify).
Q14 What actions will you take when you diagnose 
someone with both alcohol dependence and 
hypertension?
Manage and treat both problems yourself.
Manage only hypertension and refer to a general practitioner for 
management alcohol problems.
Manage only hypertension and refer to specialist care for alcohol 
problems.
Other (specify).
Q15 Which maximum amount of alcohol in g/day 
do you advise your female/male patients with 
hypertension?
Insert number, spontaneously answered.
Q16 How many of your hypertension patients have 
additional alcohol problems (in %)?
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the participants as well as awareness and implementation 
of the six recommended life style changes in the 2013 
ESH/ESC guidelines18 into clinical practice were assessed 
through part 1 (online supplementary table 2); the results 
are reported elsewhere.34 Part 2 of the survey included 
six questions (table 1), which focused exclusively on the 
awareness and implementation of the European physi-
cians regarding the role of moderation of alcohol intake 
in the management of their patients with hypertension.
Throughout the manuscript, we expressed all measures 
using consistently grams of alcohol to report amounts 
of ethyl alcohol (ethanol). According to the UK Chief 
Medical Officers,35 a unit of alcohol contains 8 g of pure 
alcohol.35
Patient and public involvement
No patients were involved in this study.
statistical analysis
Data were analysed with SPSS software (IBM SPSS Statis-
tics V.24). The number of responses available for each 
questionnaire item is reported, and relative frequencies 
are given as adjusted percentages excluding missing 
values. For each variable of interest comparisons within 
the following subgroup categories were performed: 
meeting (European: ESH/ESC vs German: DGK/DGIM), 
place of work (hospital vs practice), medical specialisa-
tion (general practitioner (GP) vs cardiologists vs inter-
nists vs other specialisations). For comparison between 
categorical variables, χ2 test analyses were performed. For 
continuous variables, t-tests or one-way analyses of vari-
ance (with Bonferroni post hoc correction for multiple 
comparisons) were applied. A two-sided p<0.05 was 
considered statistically significant.
results
The characteristics of the participating physicians are 
given in table 2. Overall, 1064 physicians (37.4% female) 
took part in the survey (806 at the European and 258 at 
the German meetings, respectively). About 20% of the 
asked physicians were not willing to participate in the 
survey. The participants were predominantly cardiologists 
(52.1%) and internists (29.2%), while 8.8% were GPs and 
78.5% of all physicians were hospital-based.
estimating proportion of patients with hypertension with 
additional alcohol problems
Participating physicians (n=946) estimated that 
18.0%±15.9% (range: 0%–95%) of their patients with 
hypertension have additional alcohol problems. Higher 
percentages were estimated by physicians attending 
the German meetings compared with their colleagues 
attending the European meetings (22.3% vs 16.8%; 
p<0.001). By their own estimates, physicians working 
in a practice reported that significantly higher rates 
of patients with hypertension have additional alcohol 
problems compared with their hospital-based colleagues 
(estimated 21.4% patients visiting a practice have addi-
tional alcohol problems vs estimated 17.2% in hospital; 
p<0.05). Concerning different medical specialisations, 
GPs estimated that a significantly higher percentage 
of their patients with hypertension (27%, p<0.001) are 
affected by additional alcohol problems compared with 
cardiologists (16.7%), internists (18.4%) or physicians 
from other specialisations (16.9%).
Quantification of alcohol consumption
Overall, 81.9% of participating physicians (n=1028) 
responded ‘yes’ to the question ‘Do you quantify alcohol 
consumption in your patients with hypertension?’ (Q11, 
table 1). Physicians attending the German meetings 
quantified the alcohol consumption of their patients with 
hypertension significantly less often than the attendees 
of the European meetings (74.5% vs 84.3%; p<0.001). 
The frequencies for quantification of alcohol consump-
tion did not show any statistically significant association 
according to place of work or specialisation of physicians 
(data not shown).
screening of alcohol consumption in different clinical settings
In the survey, 986 physicians responded to the question 
‘When do you ask for alcohol consumption in patients 
with hypertension?’ (figure 1A). Screening of alcohol 
consumption took place primarily in the context of newly 
detected hypertension (28.6%) rather than in patients 
with hypertension and very high BP (17.5%) or in patients 
with treatment-resistant hypertension (14.5%). Free-text 
answers were additionally sorted and classified into ‘Rare-
ly-never’ and ‘Always-regularly’. Overall, 55.2% of the 
respondent physicians reported regularly quantifying 
alcohol consumption in their patients with hypertension. 
When responses of the attendees at the European and 
German meetings were compared, significantly more 
physicians attending the European meetings reported 
asking about alcohol consumption in their patients 
with hypertension regularly (68.8% vs 10.8%; p<0.001; 
figure 1A).
GPs asked significantly more often (42.5%) than inter-
nists (28.2%), cardiologists (26.8%) or physicians from 
other medical specialisations (25.8%; all p<0.05) about 
alcohol consumption in patients with newly detected 
hypertension. Similar differences between GPs and physi-
cians from other specialties were observed regarding 
screening of alcohol consumption in patients with very 
high BP as well as in patients with treatment-resistant 
hypertension (figure 1B).
self-reported management or referral of patients with 
hypertension for the treatment of hypertension and/or alcohol 
problems
In patients with both hypertension and moderate to high 
alcohol consumption, 52% of the responding physicians 
(n=1021) would treat and manage both conditions by 
themselves and 10.3% would manage only hyperten-
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dependence, 13.8% would treat both hypertension and 
alcohol dependence, while 3.7% would treat only hyper-
tension without taking further action, and 64.1% would 
only treat hypertension and refer the patient to a specialist 
for the management of alcohol dependence (p<0.001). 
These differences are shown in figure 2.
In patients with moderate or high alcohol consumption 
but without alcohol dependence, 58.9% of the internists 
reported managing both hypertension and alcohol prob-
lems significantly more as compared with cardiologists 
(49.2%) and other specialists (44%; p<0.001). Differences 
between internists and GPs were not statistically significant 
(58.9% vs 52.8%; p>0.05). In addition, physicians working 
in a practice were significantly more likely to manage both 
hypertension and the alcohol problems themselves, than 
their colleagues working in a hospital (59.1% vs 50.3%; 
p<0.05). Physicians attending the German meetings 
reported managing both alcohol dependence and hyper-
tension significantly more than their colleagues attending 
the European meetings (14.7% vs 10.9%; p<0.001).









  Women 396 (37.4%) 281 (35.0%) 115 (44.6%)
  Men 664 (62.6%) 521 (65.0%) 143 (55.4%)
  Missing data 4 4 0
Age category
  20–29 years 89 (8.4%) 76 (9.5%) 13 (5%)
  30–39 261 (24.6%) 205 (25.6%) 56 (21.7%)
  40–49 310 (29.3%) 235 (29.3%) 75 (29.1%)
  50–59 274 (25.9%) 196 (24.5%) 78 (30.2%)
  60 years or older 125 (11.8%) 89 (11.1%) 36 (13.9%)
  Missing data 5 5 0
Nationality
  European countries 1004 (94.8%) 746 (93.1%) 258 (100%)
  Non-European countries 55 (5.2%) 55 (6.9%) 0
  Missing data 5 5 0
Place of work
  Practice 226 (21.5%) 130 (16.4%) 96 (37.4%)
  Hospital 824 (78.5%) 663 (83.6%) 161 (62.6%)
  Missing data 14 13 1
Specialisation
  General practitioner 93 (8.8%) 81 (10.1%) 12 (4.7%)
  Cardiologist 551 (52.1%) 443 (55.3%) 108 (42.2%)
  Internist 308 (29.1%) 200 (25.0%) 108 (42.2%)
  Other specialisation 105 (9.9%) 77 (9.6%) 28 (10.9%)
  Missing data 7 5 2
Membership
  ESH and/or ESC 494 (60.4%) 494 (87.9%) NA
  Membership in the DHL 24 (2.9%) NA 24 (9.4%)
  No ESH/ESC or DHL 
membership
300 (36.7%) 68 (12.1%) 232 (90.6%)
  Membership total 518 (63.3%) NA NA
  Missing data 246 NA 2
Numbers and percentages refer to total responses available for each item; relative frequencies are reported as adjusted percentages 
excluding missing values.
DGIM, German Society of Internal Medicine; DGK, German Society of Cardiology; DHL, German Society of Hypertension; ESC, European 
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Maximum amount of alcohol per day recommended
Physicians reported to recommend a maximum alcohol 
intake of 13.1±11.7 g/day for women (n=901 reporting 
physicians; 95% CI 12.3 to 13.8; range: 0–150) and 
19.9±15.6 g/day for men (n=884 reporting physicians; 
95% CI 18.8 to 20.9; range: 0–150).
For men, 43% of physicians recommended less than 20 g 
alcohol intake/day, 44% recommended between 20 and 
30 g/day and 13% recommended more than 30 g/day. In 
their recommendations for women, 21% recommended 
less than 10 g/day, 71% recommended 10–20 g/day women 
and 8% recommended more than 20 g/day women.
Figure 1 Proportion of physicians (%) answering the multiple choice question: ‘When do you ask for alcohol consumption in 
patients with hypertension?’ (A) Proportion of physicians (all meetings n=986) attending the European meetings compared with 
the physicians attending the German meetings. Differences are significant *p<0.05. (B) Proportion of physicians from different 
medical specialties (overall n=981); *Difference is significant p<0.05 for GP compared with each one of the other specialisations. 
BP, blood pressure; DGIM, German Society of Internal Medicine; DGK, German Society of Cardiology; ESC, European Society 
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Physicians attending the German meetings were signifi-
cantly more tolerant with their recommendations of the 
maximum amount of alcohol per day for women and 
men than their colleagues attending the European meet-
ings (15.8±9.4 g/day vs 12.1±12.2 g/day for women and 
28.3±17.5 g/day vs 16.9±13.7 g/day for men; p<0.001). 
Physicians working in a practice were consistently more 
tolerant than hospital-based physicians in their recom-
mended maximum alcohol intake for men (23.5±20.8 g/
day vs 18.8±13.6 g/day; p<0.05), but not for women 
(14.7±15.0 g/day vs 12.6±10.5 g/day; p>0.05). Significant 
differences were not observed for the alcohol intake of 
men or women between physicians belonging to different 
medical specialisations (table 3).
DIsCussIOn
The relationship between elevated BP and alcohol 
consumption is well established,7 8 and the importance 
of their burden of diseases,1–6 36 prove them as global 
public health priorities. Consequently, alcohol consump-
tion and raised BP are key parts of WHO goals to reduce 
non-communicable diseases (NCD) global NCD mortality 
by 25% by 2025.6
According to a review and meta-analysis by Roerecke 
et al,8 moderation of alcohol consumption can reduce BP 
in a dose-dependent manner in people drinking more 
than 24 g of pure alcohol per day.8 Furthermore, this 
reduction was shown to be similar to that of other life-
style changes,8 such as regular exercise37 or reduction of 
weight.38 Lifestyle changes can reduce or eliminate the 
need for antihypertensive medication in patients with 
hypertension,39–41 and their BP-lowering effects can be 
comparable to those effects achieved by drug mono-
therapy.39 40 Nevertheless, even if elevated BP and harmful 
alcohol consumption are preventable public health 
priorities, until the last 15 years, alcohol policies were 
largely not supported by sufficient research findings.42 43 
Recently, globally important public health organisations 
such as Global Alcohol Policy Alliance44 supported the 
generation of evidence-based recommendations on 
alcohol policies.44 In Europe, Alcohol Measures for Public 
Health Research Alliance (AMPHORA)45 was the first 
research project on alcohol from a public health perspec-
tive that had been cofinanced by the European Commis-
sion through the Seventh Framework Programme of 
Research.46 AMPHORA’s affiliated organisations from all 
27 member states aimed to generate scientific evidence 
about alcohol consumption and alcohol-related harm to 
help cover the European policy gap.45 In its final report 
updated in August 2013, AMPHORA reported that there 
is still a lot to be done and emphasised the need to iden-
tify more clearly which factors on a European level are 
limiting the effectiveness and implementation of alcohol 
policies.47 Therefore, our efforts assessing the awareness, 
screening and current interventions in alcohol consump-
tion in patients with hypertension among European 
physicians are very well justified.
Our analysis showed that European physicians also 
recognised a high prevalence of high BP and comorbid 
alcoholism. About 27% of the patients with hyperten-
sion have additional alcohol problems, as estimated by 
their treating physicians. Similarly, in the general popu-
lation aged 15–64 years, 300 of 1000 men consume 40 g 
of alcohol or more per day in Europe.48 Some aspects 
and practices on the management of alcohol in patients 
with hypertension observed in the current survey appear 
acceptable or positive. These include the amount of 
alcohol recommended by the participating physicians 
for both genders, which was below the thresholds recom-
mended in the European guidelines.18 In addition, more 
Figure 2 Proportion of physicians (%) answering the multiple choice question: ‘What actions will you take when you diagnose 
someone with hypertension and alcohol consumption?’ Differences are significant *p≤0.001 in case of moderate and high 
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than 80% of the physicians reported to generally quantify 
the alcohol consumption of their patients with hyperten-
sion. The screening of alcohol consumption was, however, 
very poor in some important clinical settings. Less than 
one-third of the European physicians asked about alcohol 
consumption in cases of newly detected hypertension and 
less than one-fifth asked in patients with very high BP. 
Moreover, even fewer (14.5% of the participating physi-
cians) asked patients with treatment-resistant hyperten-
sion about alcohol consumption. This result is of major 
clinical interest, because 10%–30% of patients with hyper-
tension are considered to be resistant to treatment,49 50 
and patients with treatment-resistant hypertension have 
a considerably higher risk for stroke, cardiovascular 
and kidney disease than patients with controlled hyper-
tension, as shown in multiple studies.51–54 Furthermore, 
there is good evidence that treatment-resistant hyperten-
sion can also be linked to non-adherence to moderation 
of alcohol consumption.55–57 Regarding the low number 
of physicians asking about alcohol consumption in newly 
detected hypertension, in patients with very high BP and 
in patients with treatment resistance observed in our 
current study, we cannot exclude the possibility that some 
physicians assumed that answering ‘regularly’ in our 
survey did include all of the situations mentioned above, 
although this question was read in the interview as a 
multiple choice question with the possibility of more than 
one answer (Q12 in figure 1). Moreover, even consid-
ering this possibility, only half of the interviewed physi-
cians, and also half of the GPs answered ‘regularly’ to the 
question: ‘When do you ask about alcohol consumption 
in patients with hypertension?’ These percentages of 
alcohol screening are still unsatisfactory.
In comparison to a similar study conducted exclusively 
in GPs in Europe, Rehm et al22 noted that 34% of inter-
viewed GPs reported sufficient screening of alcohol in 
patients with hypertension. However, the study design 
and questions are not fully comparable with the present 
report: The study by Rehm et al,22 was based on online 
questionnaires, and the interviewers did not ask if GPs 
quantified alcohol consumption in their hypertensive 
patients (yes/no). Instead, sufficient screening was 
assumed if GPs screened at least 7 out of 10 hyperten-
sive patients for alcohol consumption.22 In another part 
of the same study, published separately by Kraus et al,58 
less than half of the German and European patients with 
Table 3 Recommendation for alcohol intake of participating physicians
N, participating 
physicians Mean±SD 95% CI Range P values
Recommendation for alcohol intake of women (g/day) from participants of the different congresses
German meetings 231 15.8±9.4 14.6 to 17.0 0–50 P<0.001
European meetings 669 12.1±12.2 11.2 to 13.0 0–150
Recommendation for alcohol intake of men (g/day) from participants of the different congresses
German meetings 227 28.3±17.5 26.0 to 30.6 0–100 P<0.001
European meetings 662 16.9±13.7 15.9 to 18.0 0–150
Recommendation for alcohol intake of women (g/day) for the participants according to their place of work
Hospital 697 12.6±10.5 11.8 to 13.4 0–150 P=0.07
Practice 197 14.7±15.0 12.5 to 16.8 0–100
Recommendation for alcohol intake of men (g/day) for the participants according to their place of work
Hospital 689 18.8±13.6 17.8 to 19.8 0–125 P=0.04
Practice 194 23.5±20.8 20.5 to 26.4 0–150
Recommendation for alcohol intake of women (g/day) for the participants according to their medical 
specialisation
Cardiologist 471 12.8±11.3 11.8 to 13.9 0–100 P=0.35
Internist 271 14.0±13.7 12.3 to 15.6 0–150
GP 70 11.9±8.9 9.8 to 14.0 0–50
Other 84 11.9±8.2 10.2 to 13.7 0–50
Recommendation for alcohol intake of men (g/day) for the participants according to their medical 
specialisation
Cardiologist 467 19.6±16.2 18.1 to 21.1 0–150 P=0.38
Internist 266 21.1±15.5 19.2 to 22.9 0–125
GP 72 18.5±13.3 15.3 to 21.7 0–60
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hypertension in primary care were screened for alcohol 
use.58 Collectively, the findings by Rehm et al22 and Kraus 
et al58 are in agreement with our analysis concluding 
that screening for alcohol consumption in hypertensive 
patients is poor among German and European GPs and 
should be improved.
In the current survey, a significantly greater fraction 
of physicians participating in the German meetings esti-
mated that their patients exhibit both hypertension and 
alcohol problems compared with the participants at the 
European meetings. Nevertheless, a significantly greater 
fraction of physicians attending the German meet-
ings (25.5%) did not quantify alcohol consumption in 
their patients with hypertension as compared with their 
colleagues attending the European meetings (15.7%). 
Accordingly, physicians attending the German meetings 
had lower awareness of the class I level of evidence A 
recommendation on the moderation of alcohol consump-
tion contained in the ESH/ESC guidelines18 than their 
peers attending the European meetings.34 Similarly, 
Kraus et al58 reported in their survey analysis, that German 
GPs do not consider alcohol intake as a major risk for 
hypertension58 and their screening rates were slightly 
lower than the European average.58 It is arguable that 
these differences between German and European physi-
cians are due to a stronger cultural bond with alcohol 
than other European countries,59 60 which might obscure 
the perception of alcohol-related harm among German 
physicians.
The deficits identified in this study are worth over-
coming, as alcohol screening and brief intervention have 
showed positive results in many European projects.25 27 28 
Lack of resources, training and support from manage-
ment, as well as workload26 have been described as barriers 
to the adoption of screening and brief intervention.26 
We believe in the importance of finding economically 
sustainable ways of working against these barriers with the 
objective of systematising alcohol interventions. Future 
research should serve as a valuable feedback measuring 
the effects and extend of such implementation.
Among the limitations of this study, there might have 
been a bias towards inclusion of physicians who have a 
particular interest in the management of hypertension. 
In addition, reasons for non-participation were not 
recorded in our study. Also, while we recorded the nation-
ality of the participating physicians, country of practice 
was not assessed in our survey. During the conduction of 
the survey, participants who volunteered to participate 
in the survey were informed by the interviewers before 
the start of the interview that only one participation was 
allowed. As participation in the survey was voluntary with 
anonymised data collection, we cannot exclude the possi-
bility, although deemed very unlikely, of intentional or 
unintentional multiple participations. The implemen-
tation of standardised assessment of alcohol intake, like 
Alcohol Use Disorders Identification Test for Consump-
tion,61 or Severity of Alcohol Dependence Question-
naire62 or other available screening instruments, as well 
as how physicians assess and diagnose alcohol depen-
dence, were not recorded in our study. Furthermore, the 
majority of physicians participating in the survey were 
hospital based (78.5%), although long-term management 
of hypertension is predominantly carried out in an ambu-
latory setting. Moreover, because some questions were 
formulated as closed questions (ie, questions that can be 
answered with yes/no) and answers were self-reported, 
social pressure might have shifted some results upwards 
and led to an overestimation in our analysis.
In summary, European physicians recognise the high 
prevalence of comorbid hypertension and harmful 
alcohol consumption. In addition, some aspects of their 
management strategies in patients with hypertension 
regarding alcohol consumption appear adequate. In 
contrast, alcohol consumption screening in cases of newly 
detected hypertension, in patients with very high BP, and 
in treatment-resistant hypertension is very poor. Given the 
clinical importance of the latter conditions, the current 
report further supports the notion that improvements of 
awareness among European physicians on moderation of 
alcohol intake as an important modifiable lifestyle factor 
in hypertension management are necessary.
Acknowledgements  We are thankful to Angelika Thomas and Rhoda Wismer 
(signum [ pr GmbH, Cologne) for their excellent support. The survey results were 
presented at the 27th European Meeting on Hypertension and Cardiovascular 
Protection 2017 in Milan.
Contributors  LZT performed the statistical analyses, interpreted the data 
and wrote the manuscript. JB supervised the statistical analyses and revised 
the manuscript. TGR helped perform the statistical analyses with constructive 
discussion and revised the manuscript. RK conceived and designed the study, 
revised the manuscript for important intellectual content and provided supervision.
Funding  This survey was funded by Lundbeck AS (Valby, Denmark). We 
acknowledge support from the German Research Foundation (DFG) and the Open 
Access Publication Fund of Charité–Universitätsmedizin Berlin.
Competing interests  None declared. 
Patient consent  Not required. 
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
reFerenCes
 1. GBD 2016 Risk Factors Collaborators. Global, regional, and national 
comparative risk assessment of 84 behavioural, environmental and 
occupational, and metabolic risks or clusters of risks, 1990-2016: a 
systematic analysis for the Global Burden of Disease Study 2016. 
Lancet 2017;390:1345–422.
 2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends 
in blood pressure from 1975 to 2015: a pooled analysis of 
1479 population-based measurement studies with 19·1 million 
participants. Lancet 2017;389:37–55.
 3. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for 
prevention of cardiovascular disease and death: a systematic review 
and meta-analysis. Lancet 2016;387:957–67.
 4. Rehm J, Imtiaz S. A narrative review of alcohol consumption as a risk 









pen: first published as 10.1136/bmjopen-2018-022026 on 21 October 2018. Downloaded from 
9Zaidi Touis L, et al. BMJ Open 2018;8:e022026. doi:10.1136/bmjopen-2018-022026
Open access
 5. Word Health Organization, 2015. Alcohol-Fact sheet from the World 
Health Organization's Media Centre http://www. who. int/ mediacentre/ 
factsheets/ fs349/ en/ http:// www. webcitation. org/ 6v7UXNd10 
(accessed 24 Feb 2017).
 6. World Health Organization. Global status report on alcohol and 
health, 2014.
 7. Taylor B, Irving HM, Baliunas D, et al. Alcohol and hypertension: 
gender differences in dose-response relationships determined 
through systematic review and meta-analysis. Addiction 
2009;104:1981–90.
 8. Roerecke M, Kaczorowski J, Tobe SW, et al. The effect of a reduction 
in alcohol consumption on blood pressure: a systematic review and 
meta-analysis. Lancet Public Health 2017;2:e108–e20.
 9. Husain K, Ansari RA, Ferder L. Alcohol-induced hypertension: 
Mechanism and prevention. World J Cardiol 2014;6:245–52.
 10. Zhang X, Abdel-Rahman AA, Wooles WR. Impairment of 
baroreceptor reflex control of heart rate but not sympathetic efferent 
discharge by central neuroadministration of ethanol. Hypertension 
1989;14:282–92.
 11. Abdel-Rahman AA, Wooles WR. Ethanol-induced hypertension 
involves impairment of baroreceptors. Hypertension 1987;10:67–73.
 12. Russ R, Abdel-Rahman AR, Wooles WR. Role of the sympathetic 
nervous system in ethanol-induced hypertension in rats. Alcohol 
1991;8:301–7.
 13. Potter JF, Watson RD, Skan W, et al. The pressor and metabolic 
effects of alcohol in normotensive subjects. Hypertension 
1986;8:625–31.
 14. Husain K, Vazquez M, Ansari RA, et al. Chronic alcohol-induced 
oxidative endothelial injury relates to angiotensin II levels in the rat. 
Mol Cell Biochem 2008;307(1-2):51–8.
 15. Wright JW, Morseth SL, Abhold RH, et al. Elevations in plasma 
angiotensin II with prolonged ethanol treatment in rats. Pharmacol 
Biochem Behav 1986;24:813–8.
 16. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in 
cardiovascular biology and disease. Circ Res 2000;86:494–501.
 17. Alexander RW. Hypertension and the pathogenesis of 
atherosclerosis. Hypertension 1995;25:155–61.
 18. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines 
for the management of arterial hypertension: the Task Force for 
the management of arterial hypertension of the European Society 
of Hypertension (ESH) and of the European Society of Cardiology 
(ESC). J Hypertens 2013;31:1281–357.
 19. Redon J, Mourad JJ, Schmieder RE, et al. Why in 2016 are patients 
with hypertension not 100% controlled? A call to action. J Hypertens 
2016;34:1480–8.
 20. Borghi C, Tubach F, De Backer G, et al. Lack of control of 
hypertension in primary cardiovascular disease prevention 
in Europe: Results from the EURIKA study. Int J Cardiol 
2016;218:83–8.
 21. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension 
treatment, treatment intensification, and control in Western Europe 
and the United States. Arch Intern Med 2007;167:141–7.
 22. Rehm J, Prieto JA, Beier M, et al. The role of alcohol in the 
management of hypertension in patients in European primary health 
care practices - a survey in the largest European Union countries. 
BMC Fam Pract 2016;17:130.
 23. Rehm J, Gmel G, Sierra C, et al. Reduction of mortality following 
better detection of hypertension and alcohol problems in primary 
health care in Spain. Adicciones 2018;30:726.
 24. Collart F, de Timary P, Dom G, et al. Alcohol-induced hypertension: 
an important healthcare target in Belgium. Acta Clin Belg 
2015;70:389–95.
 25. Kaner EFS, Dickinson HO, Beyer FR, et al. Effectiveness of brief 
alcohol interventions in primary care populations. Cochrane 
Database Syst Rev 2007;36:Cd004148.
 26. Rehm J, Anderson P, Prieto JAA, et al. Towards new 
recommendations to reduce the burden of alcohol-induced 
hypertension in the European Union. BMC Med 2017;15:173.
 27. PHEPA Network. Primary health care European project on alcohol. 
http://www. phepa. net/ units/ phepa/ html/ en/ Du9/ index. html. Archived 
by Webcite at. http://www. webcitation. org/ 6v7Uvwrtc (accessed 10 
Mar 2016).
 28. The ODHIN project. (Optimizing delivery of health care interventions) 
2011-2014. http://www. odhinproject. eu/. http://www. webcitation. org/ 
6v7V52XGF (accessed 24 Feb 2017).
 29. Anderson P, Kaner E, Keurhorst M, et al. Attitudes and learning 
through practice are key to delivering brief interventions for heavy 
drinking in primary health care: analyses from the odhin five country 
cluster randomized factorial trial. Int J Environ Res Public Health 
2017;14:121.
 30. German Society of Cardiology. DGK Düsseldorf. https:// dgk. org/. 
Archived by Webcite at. http://www. webcitation. org/ 6v8VsEMT1 
(accessed 10 March 2016).
 31. German Society of Internal Medicine. DGIM Wiesbaden. http://
www. dgim. de/. Archived by Webcite at. http://www. webcitation. org/ 
6v8wocemO (accessed 10 March 2016).
 32. European Society of Hypertension. ESH Europe. http://www. 
eshonline. org/. Archived by Webcite at. http://www. webcitation. org/ 
6v8wyBSdH (accessed 10 Mar 2016).
 33. European Society of Cardiology. ESC Europe. https://www. escardio. 
org/. Archived by Webcite at. http://www. webcitation. org/ 6v8x6BPT3 
(accessed 10 Mar 2016).
 34. Bolbrinker J, Zaidi Touis L, Gohlke H, et al. European guidelines on 
lifestyle changes for management of hypertension : Awareness and 
implementation of recommendations among German and European 
physicians. Herz 2018;43.
 35. Alcohol Guidelines Review. Report from the Guidelines development 
group to the UK Chief Medical Officers. 44, 2016.
 36. Forouzanfar MH, Alexander L, Anderson HR, et al. Global, regional, 
and national comparative risk assessment of 79 behavioural, 
environmental and occupational, and metabolic risks or clusters 
of risks in 188 countries, 1990-2013: a systematic analysis 
for the Global Burden of Disease Study 2013. The Lancet 
2015;386:2287–323.
 37. Williamson W, Foster C, Reid H, et al. Will exercise advice be 
sufficient for treatment of young adults with prehypertension and 
hypertension? a systematic review and meta-analysis. Hypertension 
2016;68:78–87.
 38. Siebenhofer A, Jeitler K, Horvath K, et al. Long-term effects of 
weight-reducing drugs in people with hypertension. Cochrane 
Database Syst Rev 2016;3:Cd007654.
 39. Elmer PJ, Obarzanek E, Vollmer WM, et al. Effects of comprehensive 
lifestyle modification on diet, weight, physical fitness, and blood 
pressure control: 18-month results of a randomized trial. Ann Intern 
Med 2006;144:485–95.
 40. The treatment of mild hypertension study. A randomized, placebo-
controlled trial of a nutritional-hygienic regimen along with various 
drug monotherapies. The Treatment of Mild Hypertension Research 
Group. Arch Intern Med 1991;151:1413–23.
 41. Frisoli TM, Schmieder RE, Grodzicki T, et al. Beyond salt: lifestyle 
modifications and blood pressure. Eur Heart J 2011;32:3081–7.
 42. Allamani A, Voller F, Decarli A, et al. Contextual determinants of 
alcohol consumption changes and preventive alcohol policies: 
a 12-country European study in progress. Subst Use Misuse 
2011;46:1288–303.
 43. Norström T, Simpura J, Ö H, et al. Conclusions: Alcohol in postwar 
Europe: consumption, drinking patterns, consequences and 
policy responses in 15 European countries: Almqvist&Wiksell, 
2002:185–94.
 44. GAPA (Global Alcohol Policy Alliance). http:// globalgapa. org/ index. 
php/ about- us/. Archived by Webcite at. http://www. webcitation. org/ 
6v8wbf9GA (accessed 24 feb 2017).
 45. AMPHORA. Project description-The European Alcohol Policy 
Research Alliance. 2010 http://www. amphoraproject. net/ view. php? 
id_ cont= 46& PHPSESSID= ecp5 7e41 4c2g c4c7 bhafl t3i62 Archived by 
Webcite at. http://www. webcitation. org/ 6v7VN9xDY (accessed 24 
Apr 2017).
 46. European Commission. Alcohol Measures for Public Health Research 
Alliance (AMPHORA): EU Publications Office, 2009. Available 
fromArchived by Webcite at. http:// cordis. europa. eu/ project/ rcn/ 
92876_ en. html http:// www. webcitation. org/ 6v8wDS9Zt. (accessed 24 
Apr 2017).
 47. AMPHORA. Final Report Summary - AMPHORA (Alcohol Measures 
for Public Health Research Alliance): European Commission, 2013.
 48. Rehm J, Shield K, Rehm M, et al; Alcohol consumption, alcohol 
dependence, and attributable burden of disease in Europe: 
Potential gains from effective interventions for alcohol dependence, 
2012.
 49. Cai A, Calhoun DA. Resistant hypertension: an update of 
experimental and clinical findings. Hypertension 2017;70:5–9.
 50. Sim JJ, Bhandari SK, Shi J, et al. Characteristics of resistant 
hypertension in a large, ethnically diverse hypertension population of 
an integrated health system. Mayo Clin Proc 2013;88:1099–107.
 51. Sim JJ, Bhandari SK, Shi J, et al. Comparative risk of renal, 
cardiovascular, and mortality outcomes in controlled, uncontrolled 
resistant, and nonresistant hypertension. Kidney Int 2015;88:622–32.
 52. Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant 
hypertension and the incidence of cardiovascular disease and 
end-stage renal disease: results from the Antihypertensive and 









pen: first published as 10.1136/bmjopen-2018-022026 on 21 October 2018. Downloaded from 
10 Zaidi Touis L, et al. BMJ Open 2018;8:e022026. doi:10.1136/bmjopen-2018-022026
Open access 
 53. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis 
of resistant hypertension in hypertensive patients. Circulation 
2012;125:1635–42.
 54. de Beus E, Bots ML, van Zuilen AD, et al. Prevalence of apparent 
therapy-resistant hypertension and its effect on outcome in patients 
with chronic kidney disease. Hypertension 2015;66:998–1005.
 55. Diaz KM, Booth JN, Calhoun DA, et al. Healthy lifestyle factors and 
risk of cardiovascular events and mortality in treatment-resistant 
hypertension: the reasons for geographic and racial differences in 
stroke study. Hypertension 2014;64:465–71.
 56. Shimbo D, Levitan EB, Booth JN, et al. The contributions of 
unhealthy lifestyle factors to apparent resistant hypertension: 
findings from the Reasons for Geographic And Racial Differences in 
Stroke (REGARDS) study. J Hypertens 2013;31:370-6.
 57. Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension--its 
identification and epidemiology. Nat Rev Nephrol 2013;9:51–8.
 58. Kraus L, Schulte B, Manthey J, et al. Alcohol screening and alcohol 
interventions among patients with hypertension in primary health 
care: an empirical survey of German general practitioners. Addict 
Res Theory 2017;25:285–92.
 59. Anderson LMaGG P. Alcohol in the European Union. Consumption, 
harm and policy approaches: World Health Organization, 2012.
 60. Karlsson T, Simpura J. Changes in living conditions and their links to 
alcohol consumption and drinking patterns in 16 European countries, 
1950 to 2000. Nordic Studies on Alcohol and Drugs 2001;18:82–99.
 61. WHO. AUDIT: The Alcohol Use Disorders Identification Test: WHO.









pen: first published as 10.1136/bmjopen-2018-022026 on 21 October 2018. Downloaded from 
